IgE Depletion in Severe Asthma: What We Have and What Could Be Added in the Near Future

EBioMedicine

Volumn 17, Issue , 2017, Pages 16-17

  Incorvaia, Cristoforo ^a   Riario Sforza, Gian Galeazzo ^b   Ridolo, Erminia ^c  

^a ASST G Pini CTO   (Italy)

^b Sesto San Giovanni Hospital   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; B LYMPHOCYTE RECEPTOR; FC RECEPTOR IIB; IMMUNOGLOBULIN E; LIGELIZUMAB; MEDI4212; OMALIZUMAB; UNCLASSIFIED DRUG; XMAB7195; ANTIASTHMATIC AGENT;

ALLERGIC ASTHMA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DEPLETION; ASTHMA; ATOPY; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); CRYSTALLOGRAPHY; HUMAN; MAST CELL; NOTE; PHAGE DISPLAY; PHASE 1 CLINICAL TRIAL (TOPIC); PLASMA CELL; POLLEN ALLERGY; PRICK TEST; PRIORITY JOURNAL; PROTEIN DEPLETION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTI-ASTHMATIC AGENTS; ASTHMA; HUMANS; IMMUNOGLOBULIN E; OMALIZUMAB;

EID: 85014095094     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2017.02.023     Document Type: Note

References (10)

1. Arm, J.P., Bottili, I., Skerianec, A., et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin. Exp. Allergy 44 (2014), 1371–1385.
2. Chu, S.Y., Horton, H.M., Pong, E., et al. Reduction of total IgE by targeted co-engagement of IgE B-cell receptor and FcγRIib with FC-engineered antibody. J. Allergy Clin. Immunol. 129 (2012), 1102–1115.
3. Cohen, E.S., Dobson, C.L., Kack, H., et al. A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma. MAbs 6 (2014), 756–764.
4. Gauvreau, G.M., Arm, J.P., Boulet, L.P., et al. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. J. Allergy Clin. Immunol. 138 (2016), 1051–1059.
5. Incorvaia, C., Mauro, M., Riario-Sforza, G.G., et al. Current and future applications of the anti-IgE antibody omalizumab. Biologics 2 (2008), 67–73.
6. Lupinek, C., Derfler, K., Lee, S., et al. Extracorporeal IgE immunoadsorption in allergic asthma: safety and efficacy. EBioMedicine 17 (2017), 119–133.
7. Nyborg, A.C., Zacco, A., Ettinger, R., et al. Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells. Cell. Mol. Immunol. 13 (2016), 391–400.
8. Oettgen, H.C., Fifty years later: emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases. J. Allergy Clin. Immunol., 2016 (Epub ahead of print).
9. Schulman, E.S., Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am. J. Respir. Crit. Care Med. 164 (2001), S6–11.
10. Sheldon, E., Schwickart, M., Li, J., et al. Pharmacokinetics, pharmacodynamics, and safety of MEDI4212, and anti-IgE monoclonal antibody, in subjects with atopy: a phase 1 study. Adv. Ther. 33 (2016), 225–251.